SLIT Prevents the Development of Eczema in Percutaneous Allergen-Sensitized Mice  by Vanbervliet, Béatrice et al.
REFERENCES
Caux C, Dezutter-Dambuyant C, Schmitt D et al.
(1992) GM-CSF and TNF-alpha cooperate in
the generation of dendritic Langerhans cells.
Nature 360:258–61
de Jong A, Pena-Cruz V, Cheng TY et al. (2010)
CD1a-autoreactive T cells are a normal
component of the human alphabeta T cell
repertoire. Nat Immunol 11:1102–9
Dranoff G, Crawford AD, Sadelain M et al. (1994)
Involvement of granulocyte-macrophage col-
ony-stimulating factor in pulmonary homeo-
stasis. Science 264:713–6
Geissmann F, Prost C, Monnet JP et al. (1998)
Transforming growth factor beta1, in the
presence of granulocyte/macrophage col-
ony-stimulating factor and interleukin 4,
induces differentiation of human peripheral
blood monocytes into dendritic Langerhans
cells. J Exp Med 187:961–6
Hunger RE, Sieling PA, Ochoa MT et al. (2004)
Langerhans cells utilize CD1a and langerin to
efficiently present nonpeptide antigens to T
cells. J Clin Invest 113:701–8
Metcalf D (2008) Hematopoietic cytokines. Blood
111:485–91
Mohamadzadeh M, Berard F, Essert G et al.
(2001) Interleukin 15 skews monocyte
differentiation into dendritic cells with fea-
tures of Langerhans cells. J Exp Med 194:
1013–20
Pena-Cruz V, Ito S, Dascher CC et al. (2003)
Epidermal Langerhans cells efficiently med-
iate CD1a-dependent presentation of micro-
bial lipid antigens to T cells. J Invest
Dermatol 121:517–21
Sugita M, Grant EP, van Donselaar E et al. (1999)
Separate pathways for antigen presentation
by CD1molecules. Immunity 11:743–52
SLIT Prevents the Development of Eczema in
Percutaneous Allergen-Sensitized Mice
Journal of Investigative Dermatology (2012) 132, 244–246; doi:10.1038/jid.2011.278; published online 8 September 2011
TO THE EDITOR
Atopic dermatitis (AD) is a T-cell-
mediated chronic inflammatory skin
disease associated with cutaneous hy-
perreactivity to environmental antigens,
such as house dust mite Dermatopha-
goides farinae (DF), which are innoc-
uous to normal nonatopic individuals
(Bieber, 2008). The hallmarks of AD are
skin barrier dysfunction and T-cell
infiltration, which are intimately linked.
Current approaches to treating AD are
directed at both the restoration of
barrier function and the inhibition of
inflammation. Development of new
targeted therapeutic approaches is a
constant preoccupation. Sublingual im-
munotherapy (SLIT) is an efficacious
treatment for type I (IgE-mediated)
respiratory allergies (Canonica and
Passalacqua, 2006; Didier et al., 2007)
aimed at inducing allergen-specific
tolerance. Until now, SLIT is not
indicated for AD, and few data are
available for either animal models or
humans (Pajno et al., 2007). Here, we
tested the efficacy of SLIT against house
dust mite DF in a mouse model of AD,
as a proof of concept of using allergen-
specific immunotherapy in type IV
(T-cell-mediated) skin allergy. In this
DF-induced AD model, we have pre-
viously shown that CD8þ T cells
producing IFN-g are essential for the
development of AD skin inflammation
(Hennino et al., 2007). The importance
of CD8þ T cells has been previously
described in the physiopathology of the
human disease (Akdis et al., 1999;
Seneviratne et al., 2002; Hennino
et al., 2011). Upon DF skin sensitiza-
tion, CD8þ T cells are induced in
draining lymph nodes and recruited
in the challenged skin where they
initiate the AD-like skin inflammatory
reaction.
Mice were sensitized on the ear
once a week for 4 weeks by application
of a solution of DF (250 mg per applica-
tion), as previously described (Hennino
et al., 2007). Mice developed a specific
ear inflammation 24–48 hours after the
fourth DF skin challenge (day 21), but
also at distant challenge times per-
formed 4 (day 49) or 8 weeks (day 91)
later (Supplementary Figure S1A, B on-
line). Sensitized animals displayed an
average frequency of IFN-g spot-form-
ing cells (SFC) of 45 cells per 106 spleen
cells (data not shown), as detected by
the ELISPOT technique. SLIT treatment
was performed on unanesthetized mice
using chitosan-formulated DF (CHI-DF)
or the placebo control CHI-empty
particules (CHI-F) twice a week for 8
consecutive weeks (from D28 to D88)
in previously sensitized animals
(D0–D21; Figure 1a). Concentration of
DF in the particulated CHI was 8.3
times less than the immunization dose
(i.e., 30 mgml1). CHI, a polysaccha-
ride derived from chitin by deacetyla-
tion, had been previously identified to
enhance allergen-specific tolerance
when co-administrated sublingually
with the antigen in ovalbumin-sensi-
tized asthmatic mice (Razafindratsita
et al., 2007; Saint-Lu et al., 2009). As
shown in Figure 1b, mice treated with
CHI-DF did not develop DF-induced
skin inflammation 48 hours upon chal-
lenge, in contrast to placebo CHI-
F-treated mice, suggesting that SLIT
induced allergen-specific tolerance.
An important finding was also that
CHI-DF treatment of unsensitized mice
did not lead to ear inflammation upon
challenge, demonstrating that repeated
sublingual allergen exposure does not
induce sensitization. Next, we analyzed
the immune response in the spleen of
CHI-DF- or CHI-F-treated mice. Mice
were killed at day 91 and spleens were
recovered and restimulated in vitro
with DF antigen for 48 hours, and the
frequency of IFN-g-producing cells was
evaluated by ELISPOT assay. Spleen
cells were dispensed in the plates
(5105 per well) and incubated with
500mgml1 Der f protein or Der f
peptide at 2mM (data not shown) for
36 hours at 37 1C, 5% CO2 in the
presence of irradiated splenocytes as
antigen-presenting cells. To determine
Der f, class I peptide was also used for
Abbreviations: AD, atopic dermatitis; CHI, chitosan; DF, Dermatophagoides farinae; SFC, spot-forming
cells; SLIT, sublingual immunotherapy
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restimulation at a final concentration of
2 mM. The peptide 113–122 sequence
(YGISNYCQI) was determined by pre-
diction using the BioInformatics and
Molecular Analysis Section and SYF-
PEITHI epitope prediction databases.
Mice treated with placebo CHI-F
showed a high frequency of allergen-
specific IFN-g-producing cells in the
spleen (Figure 1b). In contrast, mice
treated with CHI-DF showed a signifi-
cant reduction of IFN-g SFC, which was
comparable with the frequency found
in unsensitized mice (Figure 1b). These
data suggest that allergen-specific SLIT
is associated with a drastic reduction in
the induction of DF-specific effector
T cells.
As specific immunotherapy was
shown to promote the production of
IL-10 (Piconi et al., 2010), we have
further analyzed the immune response
in the lymph nodes draining the SLIT
mucosal sites (i.e., the sublingual lymph
nodes). SLIT-draining lymph nodes were
recovered at 91 days and restimulated
in vitro with DF antigen for 48hours; the
production of IL-10 was evaluated
by ELISA. As shown in Figure 2a,
DF-sensitized mice treated with CHI-
DF displayed an enhanced production
of IL-10 compared with CHI-F-treated
mice. It is noteworthy that IL-10 was
specifically induced by SLIT treatment
and was independent of the sensitization
as CHI-DF-treated unsensitized mice
also showed increased IL-10 production.
Finally, we analyzed the production of
serum IgE in the different groups of
mice. Consistent with our previous
study (Hennino et al., 2007), DF-sensi-
tized mice treated with the CHI-F
placebo SLIT developed increased IgE
levels (mean 120±60ngml1). CHI-DF
immunotherapy increased the levels
of serum IgE in both DF-sensitized
(mean 500±80ngml1) and unsensi-
tized (mean 68±30ngml1) mice,
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Figure 1. Sublingual immunotherapy (SLIT) prevents development of atopic dermatitis in sensitized animals. (a) Schematic protocol used for the study.
(b) Dermatophagoides farinae (DF)-induced skin inflammation was analyzed at day 93 (48 hours post challenge). Results are expressed as the mean
ear swelling (i.e., ear thickness of the DF-challenged right ear minus the ear thickness of the vehicle (DMSO 70%)-challenged right ear) and are
representative of three independent experiments, using five mice per group. (c) DF-specific IFN-g-producing cells were determined in total spleen cells
at day 91. Results are expressed as the number of spot-forming cells (SFC) per 106 spleen cells. Results are representative of three independent experiments.
*Po0.05 using unpaired t-test. CHI-DF, chitosan-formulated DF.
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Figure 2. Sublingual immunotherapy (SLIT) induces IL-10 and IgE production. (a) Dermatophagoides farinae (DF)-specific production of IL-10 by
SLIT-draining lymph node cells (day 91) after in vitro restimulation with DF (ELISA). (b) Total serum IgE levels (in ngml1) at day 93. Results are representative
of three independent experiments. **Po0.05 using two-tailed unpaired t-test. CHI-DF, chitosan-formulated DF.
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demonstrating that mucosal exposure to
DF is able to induce IgE production in
naive mice and boost IgE production in
mice already sensitized through the skin.
This observation indicates that there is no
correlation between SLIT-induced im-
provement of AD skin inflammation and
IgE serum levels. Along this line, we have
previously shown that the development
of AD skin lesions was not influenced by
serum IgE levels, as MHC II/ mice,
lacking CD4þ T cells and therefore
unable to produce IgE, developed even
more severe AD skin lesions than wild-
type mice (Hennino et al., 2007).
In summary, we provide evidence
that SLIT is efficient in a mouse model
of AD, in which sensitized animals
display high numbers of allergen-spe-
cific T cells. Systematic studies on the
effectiveness of SLIT in patients with
AD are rare. Two clinical studies, one
in adults and one in children with
specific IgE to house dust mite, showed
that SLIT or subcutaneous immunother-
apy improved mild–moderate atopic
dermatitis (Werfel et al., 2006; Pajno
et al., 2007). DF SLIT treatment led to
decreased numbers of specific T cells,
increased production of IL-10, and
enhanced protection from DF-induced
skin inflammation upon challenge. We
therefore postulate that SLIT could be
considered as an attractive treatment
for AD in well-defined patients, without
polysensitization relying on the pres-
ence of antigen-specific T cells for a
defined Ag (i.e., Der f or Der p) in
peripheral blood or on positive atopy
patch test to the allergen (Nosbaum
et al., 2010).
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TO THE EDITOR
Psoriasis vulgaris is a chronic disease
that affects 1–3% of the population
(Chandran and Raychaudhuri, 2010).
In addition to skin and possible joint
involvement, recent evidence suggests
associations between psoriasis and
other systemic diseases (Gelfand et al.,
2006). The molecular characterization
of psoriatic skin samples has led to
a greater understanding of disease
pathogenesis and has been useful inAbbreviations: DEG, differentially expressed gene; FC, fold change; TNF-a, tumor necrosis factor-a
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